[go: up one dir, main page]

MA37945B1 - Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées - Google Patents

Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées

Info

Publication number
MA37945B1
MA37945B1 MA37945A MA37945A MA37945B1 MA 37945 B1 MA37945 B1 MA 37945B1 MA 37945 A MA37945 A MA 37945A MA 37945 A MA37945 A MA 37945A MA 37945 B1 MA37945 B1 MA 37945B1
Authority
MA
Morocco
Prior art keywords
methods
antibodies
gfr3
human antibodies
present
Prior art date
Application number
MA37945A
Other languages
English (en)
Other versions
MA37945A1 (fr
Inventor
Lynn Macdonald
Andrew J Murphy
Susan D Croll
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49036666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37945(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA37945A1 publication Critical patent/MA37945A1/fr
Publication of MA37945B1 publication Critical patent/MA37945B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)

Abstract

La présente invention concerne des anticorps qui se lient au gfra3 humain et des méthodes d'utilisation associées. Selon certains modes de réalisation décrits dans la présente invention, les anticorps sont des anticorps entièrement humains qui se lient au gfra3 humain. Les anticorps de la présente invention sont utiles dans le traitement de maladies et de troubles associés à une ou plusieurs activités biologiques du gfra3, y compris le traitement d'états associés à une douleur aiguë ou chronique, ou des états inflammatoires.
MA37945A 2012-08-22 2013-08-21 Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées MA37945B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692029P 2012-08-22 2012-08-22
PCT/US2013/055921 WO2014031712A1 (fr) 2012-08-22 2013-08-21 Anticorps humains dirigés contre le gfrα3 et méthodes d'utilisation associées

Publications (2)

Publication Number Publication Date
MA37945A1 MA37945A1 (fr) 2016-02-29
MA37945B1 true MA37945B1 (fr) 2017-05-31

Family

ID=49036666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37945A MA37945B1 (fr) 2012-08-22 2013-08-21 Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées

Country Status (34)

Country Link
US (5) US8968736B2 (fr)
EP (2) EP3450458B1 (fr)
JP (3) JP6392755B2 (fr)
KR (1) KR102158569B1 (fr)
CN (2) CN109096398A (fr)
AR (1) AR092188A1 (fr)
AU (1) AU2013305863B2 (fr)
CA (1) CA2879724C (fr)
CL (1) CL2015000420A1 (fr)
CY (1) CY1121097T1 (fr)
DK (1) DK2888280T3 (fr)
EA (2) EA034683B1 (fr)
ES (1) ES2700160T3 (fr)
HR (1) HRP20190109T1 (fr)
HU (1) HUE042943T2 (fr)
IL (1) IL236738B (fr)
JO (1) JO3462B1 (fr)
LT (1) LT2888280T (fr)
MA (1) MA37945B1 (fr)
MX (1) MX363541B (fr)
MY (2) MY167920A (fr)
NZ (1) NZ704007A (fr)
PH (1) PH12015500114A1 (fr)
PL (1) PL2888280T3 (fr)
PT (1) PT2888280T (fr)
RS (1) RS58311B1 (fr)
SG (2) SG11201500501VA (fr)
SI (1) SI2888280T1 (fr)
SM (1) SMT201900022T1 (fr)
TR (1) TR201816597T4 (fr)
TW (2) TWI631139B (fr)
UY (1) UY34988A (fr)
WO (1) WO2014031712A1 (fr)
ZA (1) ZA201500336B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX362456B (es) 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
WO2016025884A1 (fr) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Anticorps spécifique de l'alpha-récepteur 4 de la famille des gdnf (gfralpha4) lié au glycosyl-phosphatidylinositol (gpi) et ses utilisations
JP2019506412A (ja) * 2016-02-10 2019-03-07 ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
US20170281756A1 (en) * 2016-02-25 2017-10-05 University Of Southern California Compositions and methods to selectively block pain induced by cold
EP3423094A4 (fr) * 2016-02-29 2019-11-06 Eli Lilly and Company Traitements impliquant le récepteur gfral
IL261666B2 (en) * 2016-03-31 2024-09-01 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
MX2018013885A (es) 2016-05-13 2019-08-16 Inst De Medicina Molecular Joaeo Lobo Antunes Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3).
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CN107827983B (zh) * 2017-11-06 2020-09-25 中国药科大学 一种靶向artn的单链抗体、制备方法及应用
US20220064274A1 (en) * 2018-03-26 2022-03-03 Shanghai Yile Biotechnology Co., Ltd. Use of probdnf regulator in b cell-related diseases
WO2019210144A1 (fr) * 2018-04-27 2019-10-31 Vanderbilt University Anticorps largement neutralisants dirigés contre le virus de l'hépatite c
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
JP2022519118A (ja) * 2019-02-01 2022-03-18 ノヴァロック バイオセラピューティクス， リミテッド 抗クローディン１８抗体及びそれらの使用の方法
WO2020210551A1 (fr) * 2019-04-10 2020-10-15 Regeneron Pharmaceuticals, Inc. Anticorps humains qui se lient au ret et leurs procédés d'utilisation
US11802159B2 (en) 2019-09-30 2023-10-31 The Trustees Of The University Of Pennsylvania Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs)
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2022225985A1 (fr) 2021-04-20 2022-10-27 Regeneron Pharmaceuticals, Inc. Anticorps humains dirigés contre l'artémine et leurs procédés d'utilisation
US20240270855A1 (en) 2021-06-03 2024-08-15 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
US20250154236A1 (en) * 2022-01-31 2025-05-15 Glaxosmithkline Intellectual Property (No. 3) Limited Prevention and treatment of headaches
WO2024155798A1 (fr) * 2023-01-18 2024-07-25 Texas Tech University System Anticorps gfra2 et leur utilisation dans le traitement du cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
IL138593A0 (en) 1998-03-23 2001-10-31 Genentech Inc GFRα3 AND ITS USES
WO2000004050A2 (fr) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Facteur de croissance neurotrophique
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008546716A (ja) * 2005-06-17 2008-12-25 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ＧＦＲα３抗体
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
US8409577B2 (en) * 2006-06-12 2013-04-02 Emergent Product Development Seattle, Llc Single chain multivalent binding proteins with effector function
US20090252729A1 (en) * 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
AU2008278803A1 (en) 2007-07-25 2009-01-29 Astrazeneca Ab Targeted binging agents directed to KDR and uses thereof - 035
US20110135648A1 (en) 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
WO2012077649A1 (fr) * 2010-12-06 2012-06-14 大日本住友製薬株式会社 Anticorps monoclonal humain
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها

Also Published As

Publication number Publication date
CN104768974B (zh) 2018-08-14
CN109096398A (zh) 2018-12-28
CY1121097T1 (el) 2019-12-11
LT2888280T (lt) 2018-12-10
BR112015003110A2 (pt) 2018-08-28
TR201816597T4 (tr) 2018-11-21
WO2014031712A1 (fr) 2014-02-27
EP3450458A1 (fr) 2019-03-06
EA202090031A2 (ru) 2020-04-30
MX363541B (es) 2019-03-27
AR092188A1 (es) 2015-04-08
HUE042943T2 (hu) 2019-07-29
EP2888280B1 (fr) 2018-10-17
UY34988A (es) 2014-03-31
US20140056903A1 (en) 2014-02-27
AU2013305863B2 (en) 2018-06-07
AU2013305863A1 (en) 2015-02-05
NZ704007A (en) 2018-08-31
JP2020031662A (ja) 2020-03-05
MY184241A (en) 2021-03-29
KR102158569B1 (ko) 2020-09-22
EA201590402A1 (ru) 2015-09-30
JP2018143252A (ja) 2018-09-20
JO3462B1 (ar) 2020-07-05
KR20150041664A (ko) 2015-04-16
DK2888280T3 (en) 2018-12-10
CN104768974A (zh) 2015-07-08
PH12015500114B1 (en) 2015-03-16
MX2015002289A (es) 2016-06-07
SMT201900022T1 (it) 2019-02-28
JP6392755B2 (ja) 2018-09-19
CA2879724C (fr) 2023-03-14
US10947312B2 (en) 2021-03-16
US10077311B2 (en) 2018-09-18
RS58311B1 (sr) 2019-03-29
JP2015532647A (ja) 2015-11-12
JP6718482B2 (ja) 2020-07-08
US8968736B2 (en) 2015-03-03
PT2888280T (pt) 2019-01-21
IL236738B (en) 2022-04-01
ZA201500336B (en) 2019-12-18
EP3450458B1 (fr) 2021-07-14
TW201420603A (zh) 2014-06-01
SG10201701376UA (en) 2017-03-30
EA034683B1 (ru) 2020-03-05
IL236738A0 (en) 2015-02-26
CL2015000420A1 (es) 2015-05-22
EA202090031A3 (ru) 2020-07-31
PL2888280T3 (pl) 2019-04-30
US20170096488A1 (en) 2017-04-06
HRP20190109T1 (hr) 2019-03-08
TWI631139B (zh) 2018-08-01
PH12015500114A1 (en) 2015-03-16
MA37945A1 (fr) 2016-02-29
ES2700160T3 (es) 2019-02-14
SG11201500501VA (en) 2015-02-27
HK1206037A1 (en) 2015-12-31
US20150110801A1 (en) 2015-04-23
TW201819415A (zh) 2018-06-01
MY167920A (en) 2018-09-27
US9522185B2 (en) 2016-12-20
US20200040087A1 (en) 2020-02-06
US20180340029A1 (en) 2018-11-29
EP2888280A1 (fr) 2015-07-01
SI2888280T1 (sl) 2019-03-29
TWI613218B (zh) 2018-02-01
CA2879724A1 (fr) 2014-02-27

Similar Documents

Publication Publication Date Title
MA37945B1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
FR22C1052I2 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
EA201370081A1 (ru) Антитела к cd48 и их применение
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
EP2774616A4 (fr) Application de roseburia dans le traitement et la prévention de maladies liées à l'obésité
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
MA47130A (fr) Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
MA38478A1 (fr) Anticorps anti-pac1 humains
HK1220468A1 (zh) Nav1．7的人抗体
EP2170950A4 (fr) Anticorps anti-il-20 et son utilisation dans le traitement de maladies inflammatoires associées à il-20
EP4289861A4 (fr) Anticorps contre la tslp humaine et leur utilisation
PH12012502215A1 (en) Anti-fgfr2 antibodies
MA34818B1 (fr) Anticorps anti-pcsk9 et procédés d'utilisation
MY159551A (en) High affinity human antibodies to human protease-activated receptor-2
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
BRPI0821658A2 (pt) Anticorpos contra nkg2d humano e usos dos mesmos
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
EP2629795A4 (fr) Anticorps humains et leurs utilisations diagnostiques et thérapeutiques dans le traitement de troubles neurologiques
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation
MA38501B1 (fr) Anticorps humains de la protéine f du virus respiratoire syncytial et ses procédés d'utilisation
MA35936B1 (fr) Anticorps d'anti-big-endothéline-1 (big-et-1) et utilisations associées
MA38003A1 (fr) Anticorps anti-récepteur de prokinéticine (prokr) et leurs utilisations
MA38503A1 (fr) Anticorps anti-il-33 et leurs utilisations